Stay updated on Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.

Latest updates to the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page
- Check5 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the previous trial details with an access-denied screen. This indicates the study record is temporarily unavailable to users.SummaryDifference21%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedRevision tag updated from v3.6.5 to v3.6.6 on the page, indicating a newer version of the ClinicalTrials.gov entry. This reflects a page refresh or minor metadata update without altering the study details.SummaryDifference0.1%

- Check47 days agoChange DetectedThe revision label on the page was updated from v3.6.4 to v3.6.5, signaling a minor patch. No visible study details or core functionality are affected.SummaryDifference0.0%

- Check62 days agoChange DetectedThe page revision label was updated from v3.6.3 to v3.6.4, indicating a software update. The underlying study information and user-facing content remain unchanged.SummaryDifference0.0%

- Check83 days agoChange DetectedFooter text now includes Moffitt center branding and a new revision tag (v3.6.3). The old revision tag (v3.6.2) was removed.SummaryDifference0.2%

- Check90 days agoChange DetectedThe page's revision tag was updated to v3.6.2 from v3.6.0, signaling a new version of the page metadata. This update reflects documentation/version control activity rather than changes to the study data.SummaryDifference0.0%

Stay in the know with updates to Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.